BSH 2022 | Venetoclax + azacitidine in unfit patients with AML
Pramila Krishnamurthy, MD, King’s College Hospital NHS Foundation Trust, London, UK, discusses the treatment of patients with acute myeloid leukemia (AML) with venetoclax and azacitidine, and the recent approval for reimbursement of this combination by NICE in patients who are unsuitable for treatment with intensive chemotherapy. Dr Krishnamurthy notes that this combination is particularly useful for older patients with AML. Data from VIALE-A (NCT02993523) reported a higher overall survival (OS) in patients treated with azacitidine-venetoclax versus those in the control group (azacitidine-placebo). Dr Krisnamurthy also mentions that the mutational profile of patients may predict response to treatment, with some mutations increasing the risk of relapse in some patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Ad board- Jazz
Honorarium- Astellas, Jazz
